Actively Recruiting
Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK
Led by Creo Medical Limited · Updated on 2026-04-21
18
Participants Needed
2
Research Sites
72 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study involves the use of a medical device, the Creo Medical MicroBlate Flex instrument, to heat and destroy lung tumour cells using microwave energy (this is also called ablation). In this study, the investigators are investigating whether the ablation instrument can be used effectively to treat lung tumours or tumours that have spread to the lungs. If successful, using this technology may mean future patients may not need to undergo surgical removal of these types of lung tumours. The aim of this study is to evaluate the safety and performance of the MicroBlate Flex instrument in treating individuals with cancerous lung tumours that are due to be removed by surgery. All participants in the study will undergo the microwave ablation procedure, which is a separate and additional procedure to their surgical procedure. The study, funded by Creo Medical, will be conducted at sites in the UK and Italy, and will involve up to 18 participants.
CONDITIONS
Official Title
Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates - UK
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent to participate in the study
- Willing and able to follow all treatment and evaluation schedules
- Age 18 years or older
- Lung lesion(s) confirmed as cancer by tissue tests
- Lung lesions 20 mm or smaller in largest size by pulmonary window
- Candidate for surgical lung tumor removal as decided by a medical team
- At least 10 mm of tumor-free lung tissue between tumor and pleura or fissure
- Able and willing to comply with study requirements
- Assigned an ASA score of 3 or lower or considered fit for general anesthesia
You will not qualify if you...
- Lung nodules located in the International Association for the Study of Lung Cancer (IASLC) "Central Zone" (including bronchial tree, major vessels, heart, esophagus, spinal cord, and phrenic & laryngeal nerves)
- Pregnant or breastfeeding
- Participated in another investigational drug or device study within 30 days before enrollment
- Physical or psychological conditions that impair participation or safety
- Expected survival less than 12 months
- Have implantable devices such as pacemakers or other electronic implants
- Known pulmonary hypertension with pulmonary artery systolic pressure over 50 mmHg
- Previous lung removal surgery (pneumonectomy)
- Diagnosis of Small Cell Lung Cancer
- Prior therapeutic intervention (e.g., SBRT) in the same lung lobe as target lesion
- Undergoing or had chemotherapy, immunosuppressive treatment, or radiotherapy within 3 months before planned study procedure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Istituto Europeo di Oncologia (IEO), Via Ripamonti 435
Milan, Italy, 20141
Not Yet Recruiting
2
Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital, Sydney Street
London, UK, United Kingdom, SW3 6NP
Actively Recruiting
Research Team
C
Charlie Campion
CONTACT
A
Annie Goulding
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here